METHSUXIMIDE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for METHSUXIMIDE (METHSUXIMIDE).

How it works

Succinimide anticonvulsant; reduces low-threshold T-type calcium currents in thalamic neurons, thereby suppressing paroxysmal depolarizations and spike-wave activity associated with absence seizures.

What the body does with it

Metabolism	Metabolized hepatically, primarily via hydroxylation by CYP450 enzymes (CYP3A4, CYP2C9, CYP2C19) to an active metabolite, N-desmethylmethsuximide; <1% excreted unchanged in urine.
Excretion	Renal: ~85% (50% as parent drug, 35% as inactive metabolites); Fecal: <5%; Biliary: negligible
Half-life	Terminal elimination half-life: 1.5–4.5 hours (mean ~2.5 hours) in adults; shorter in children. Requires multiple daily doses for therapeutic concentration maintenance.
Protein binding	Negligible; <5% bound (does not bind significantly to albumin or other plasma proteins).
Volume of Distribution	Vd: 0.8–1.2 L/kg (suggests distribution into total body water; no extensive tissue binding).
Bioavailability	Oral: ~90% (well absorbed; minimal first-pass metabolism).
Onset of Action	Oral: 30–60 minutes (therapeutic effect on absence seizures may take 3–6 days). Intravenous: N/A (not available).
Duration of Action	Duration: 6–8 hours; due to short half-life, dosing 3–4 times daily is needed. Steady-state achieved in 2–3 days.

Classification & Brands

Dosing & administration

Initial: 300 mg orally once daily for first week; increase by 300 mg weekly up to 1.2 g/day in 2-3 divided doses. Maintenance: 600-1200 mg/day in 2-3 divided doses.

Dosage form	CAPSULE
Renal impairment	No specific guidelines; use with caution in severe renal impairment (GFR <30 mL/min) with monitoring for toxicity; consider dose reduction.
Liver impairment	Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
Pediatric use	Initial: 10 mg/kg/day in 2-3 divided doses, increase weekly by 5 mg/kg/day; maximum 30 mg/kg/day or 1.2 g/day, whichever is less.
Geriatric use	Initiate at low end of dosing range (300 mg/day) due to age-related reduced renal function; titrate slowly with monitoring for CNS effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for METHSUXIMIDE (METHSUXIMIDE).

Breastfeeding	Present in breast milk with M/P ratio of 1.1. Limited data suggest low infant exposure; however, monitor for sedation and poor feeding. Benefits of breastfeeding may outweigh risks with caution.
Teratogenic Risk	First trimester: Associated with increased risk of congenital malformations, including oral clefts, cardiac defects, and neural tube defects. Second and third trimesters: Risk of fetal hydantoin syndrome, intrauterine growth restriction, and neurodevelopmental deficits. Neonatal hemorrhage due to vitamin K deficiency is possible.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Absolute: Hypersensitivity to succinimides (e.g., methsuximide, ethosuximide) or any component of the formulation.","Relative: Concomitant use with MAOIs (potential for severe CNS depression)."]

Clinical Precautions

Precautions

["May cause drowsiness, dizziness, or blurred vision; caution in activities requiring mental alertness.","Abrupt withdrawal may precipitate status epilepticus.","May exacerbate grand mal (tonic-clonic) seizures; use with caution in mixed seizure types.","Hematologic effects: Case reports of leukopenia, pancytopenia; monitor CBC periodically.","Hepatic effects: Rare reports of hepatotoxicity; monitor LFTs.","Rash may indicate serious hypersensitivity (e.g., SJS/TEN); discontinue if rash appears.","Renal effects: Monitor renal function in patients with pre-existing impairment.","Pregnancy: Pregnancy Category C; may cause fetal harm; consider alternative therapy."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

METHSUXIMIDE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for METHSUXIMIDE (METHSUXIMIDE).

How it works

Succinimide anticonvulsant; reduces low-threshold T-type calcium currents in thalamic neurons, thereby suppressing paroxysmal depolarizations and spike-wave activity associated with absence seizures.

What the body does with it

Metabolism	Metabolized hepatically, primarily via hydroxylation by CYP450 enzymes (CYP3A4, CYP2C9, CYP2C19) to an active metabolite, N-desmethylmethsuximide; <1% excreted unchanged in urine.
Excretion	Renal: ~85% (50% as parent drug, 35% as inactive metabolites); Fecal: <5%; Biliary: negligible
Half-life	Terminal elimination half-life: 1.5–4.5 hours (mean ~2.5 hours) in adults; shorter in children. Requires multiple daily doses for therapeutic concentration maintenance.
Protein binding	Negligible; <5% bound (does not bind significantly to albumin or other plasma proteins).
Volume of Distribution	Vd: 0.8–1.2 L/kg (suggests distribution into total body water; no extensive tissue binding).
Bioavailability	Oral: ~90% (well absorbed; minimal first-pass metabolism).
Onset of Action	Oral: 30–60 minutes (therapeutic effect on absence seizures may take 3–6 days). Intravenous: N/A (not available).
Duration of Action	Duration: 6–8 hours; due to short half-life, dosing 3–4 times daily is needed. Steady-state achieved in 2–3 days.

Classification & Brands

Dosing & administration

Initial: 300 mg orally once daily for first week; increase by 300 mg weekly up to 1.2 g/day in 2-3 divided doses. Maintenance: 600-1200 mg/day in 2-3 divided doses.

Dosage form	CAPSULE
Renal impairment	No specific guidelines; use with caution in severe renal impairment (GFR <30 mL/min) with monitoring for toxicity; consider dose reduction.
Liver impairment	Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
Pediatric use	Initial: 10 mg/kg/day in 2-3 divided doses, increase weekly by 5 mg/kg/day; maximum 30 mg/kg/day or 1.2 g/day, whichever is less.
Geriatric use	Initiate at low end of dosing range (300 mg/day) due to age-related reduced renal function; titrate slowly with monitoring for CNS effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for METHSUXIMIDE (METHSUXIMIDE).

Breastfeeding	Present in breast milk with M/P ratio of 1.1. Limited data suggest low infant exposure; however, monitor for sedation and poor feeding. Benefits of breastfeeding may outweigh risks with caution.
Teratogenic Risk	First trimester: Associated with increased risk of congenital malformations, including oral clefts, cardiac defects, and neural tube defects. Second and third trimesters: Risk of fetal hydantoin syndrome, intrauterine growth restriction, and neurodevelopmental deficits. Neonatal hemorrhage due to vitamin K deficiency is possible.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Absolute: Hypersensitivity to succinimides (e.g., methsuximide, ethosuximide) or any component of the formulation.","Relative: Concomitant use with MAOIs (potential for severe CNS depression)."]